TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05895539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An automated patient-reported outcome data collection and adverse event surveillance tool
Description: Patients received a short prompt to provide information on treatment satisfaction and side effects
Study: NCT03676504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 3 days of cyclophosphamide 500 mg/m\^2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 3 days of cyclophosphamide 500 mg/m\^2/day
Study: NCT03190148

Intervention type: OTHER
Group type: OTHER
Intervention: OGTT
Description: A standardized 75g oral Glucose tolerance test was accomplished.

Intervention type: OTHER
Group type: OTHER
Intervention: OGTT
Description: A standardized 75g oral Glucose tolerance test was accomplished.

Intervention type: OTHER
Group type: OTHER
Intervention: OGTT
Description: A standardized 75g oral Glucose tolerance test was accomplished.

Intervention type: OTHER
Group type: OTHER
Intervention: IVGTT
Description: For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished

Intervention type: OTHER
Group type: OTHER
Intervention: IVGTT
Description: For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished

Intervention type: OTHER
Group type: OTHER
Intervention: IVGTT
Description: For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished

Intervention type: OTHER
Group type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery

Intervention type: OTHER
Group type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery

Intervention type: OTHER
Group type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
Study: NCT03026166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Administered by intravenous infusion
Study: NCT01758068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coconut Oil Application
Description: Coconut oil - 4 ml
Study: NCT04266821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case.
Study: NCT02708771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 daily capsules of similar appearance and flavor without active ingredient
Study: NCT01010113

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard infant formula with prebiotics
Description: From 0-6 months of age. As per standard requirement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with synbiotics
Description: From 0-6 months of age as per standard requirement
Study: NCT02198235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study: NCT05106010

Intervention type: OTHER
Intervention: Balance Flow Yoga
Description: The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
Study: NCT02530996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4
Description: BH4 10 mg/kg/day given once to a total of 12 SSc patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4
Description: BH4 10 mg/kg/day given once to a total of 12 SSc patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vasculopathy assessment
Description: Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vasculopathy assessment
Description: Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
Study: NCT01742065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auto Plus
Description: Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
Study: NCT05620953

Intervention type: DIAGNOSTIC_TEST
Intervention: respiratory specimen
Description: nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
Study: NCT00042666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY317615
Description: 500 mg, oral, QD, up to six 28 day cycles
Study: NCT00805064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone and bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone and bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone and bevacizumab
Study: NCT04608422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
Study: NCT04496453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childhood vaccination decision support tool
Description: Participants receive childhood vaccination decision support tool
Study: NCT01573481

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure support ventilation
Description: Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled ventilation
Description: Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
Study: NCT03083223

Intervention type: OTHER
Intervention: position
Description: Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
Study: NCT01086852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FACTOR X
Description: Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min.
Study: NCT03299283

Intervention type: DIAGNOSTIC_TEST
Intervention: BioFire test platform
Description: Analysis of analyte stability under various conditions as measured by BioFire test platforms

Intervention type: DIAGNOSTIC_TEST
Intervention: BioFire test platform
Description: Analysis of analyte stability under various conditions as measured by BioFire test platforms
Study: NCT02575703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3023414
Description: LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
Study: NCT03006224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Lung Ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Lung Ventilation
Study: NCT03000036

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).

Intervention type: DEVICE
Group type: OTHER
Intervention: Achieva, Philips Medical Systems (3T magnet)
Description: Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.

Intervention type: DRUG
Group type: OTHER
Intervention: Gadoterate Meglumine
Description: LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
Study: NCT04571996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-104
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Rapidly dissolving tablet
Study: NCT02048371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Study: NCT04306835

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy for insomnia
Description: a technique for treating insomnia without medications
Study: NCT02048371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 days on and 7 days off
Study: NCT04698694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)
Description: The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)
Description: The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
Study: NCT00972920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Description: Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
Study: NCT03720496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-TriCAR-T
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
Study: NCT00796107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: R1507 was administered at a dose 16 mg/kg every 3 weeks.
Study: NCT03375411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent INC1
Description: Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
Study: NCT00523250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-102 0.003% Ophthalmic Solution
Study: NCT00796107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole was administered orally at a dose 2.5 mg daily.
Study: NCT04003792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: intra-arterial oxaliplatin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: systemic FOLFIRI chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: systemic bevacuzimab therapy
Study: NCT03964779

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal assay
Description: Measurement of Thyroid stimulating hormone

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal assay
Description: Measurement of Thyroid stimulating hormone

Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal assay
Description: Measurement of Thyroid stimulating hormone

Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody assay
Description: antithyroglobulin and antithyroid peroxidase

Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody assay
Description: antithyroglobulin and antithyroid peroxidase

Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody assay
Description: antithyroglobulin and antithyroid peroxidase
Study: NCT02218554

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRONJ
Description: collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
Study: NCT04153903

Intervention type: OTHER
Intervention: OCT, coronary angiography, FFR
Description: Coronary images by OCT and angiography and FFR values will be registered.
Study: NCT03959111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation at Location 1
Description: Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation at Location 2
Description: Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
Study: NCT01662401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
Study: NCT03743155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal cells
Description: Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
Study: NCT03685812

Intervention type: DIAGNOSTIC_TEST
Intervention: Autocad software
Description: The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
Study: NCT04414618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opaganib
Description: Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
Study: NCT03451357

Intervention type: DIAGNOSTIC_TEST
Intervention: Dependence degree already certificated by Dependence Law.
Description: The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
Study: NCT02048371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 days on and 7 days off
Study: NCT00076349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine and rituximab
Description: Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.